Navigation Links
2009 Pharma ChemOutsourcing Show Attendance Up an Astounding 60% Despite Current Recession
Date:6/3/2009

LONG BRANCH, N.J., June 3 /PRNewswire/ -- The 2009 Pharma ChemOutsourcing Conference & Exhibition attendance is way up again in 2009 and is poised to shatter the attendance record set in 2008. The remarkable success of last year's meeting generated the positive buzz responsible for much of the growth. Attendance for the September 14-16, 2009 event is expected to be about 1000.

Also attracting high attendance is the conference program newly focused on the outsourcing needs of small molecule biotech companies, today's drivers behind much of the growth of the pharmaceutical industry, reports Mark Alexay of Apaporis LLC, the organizer. In 2009, 35 different biotech company chemists are participating as speakers.

The high interest in the new biotech track offers biotech company process and medicinal chemistry, supply chain and manufacturing management personnel opportunity to share their chemical sourcing experiences and strategies. Given the small size of most of the firms, the 35 speakers provide a rare glimpse into the challenges they face to secure external suppliers to do their scale up manufacturing. The track may be viewed at http://www.chemoutsourcing.com/agenda.trackd.php

Biotech participants include speakers from King Pharmaceuticals, Medivation, GPC Biotech, Theravance, Bionumerik Pharmaceuticals, Anthera Pharmaceuticals, Palatin Technologies, Magen Biosciences, Inspire Pharmaceuticals, Geron Pharmaceuticals, Phenomix Corporation and CoNCERT Pharmaceuticals.

The show will take place at the beachfront Ocean Place Resort in Long Branch, NJ. The high end venue affords beach area for nightly barbecues and parties to facilitate informal networking. The show kicks off on Sunday, September 13 and ends Wednesday, September 1
'/>"/>

SOURCE Apaporis LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...swire-USNewswire/ -- The Michael J. Fox Foundation...1.5 million in total awards to six research teams ...herapies for Parkinson,s disease. The funding was ...ery for Parkinson,s Disease program, made possibl...LN ), a neuroscience-based biotechnology company. ...
(Date:11/30/2009)...re/ -- Dr. Jessica Torrente, Assistant Professor o...l Center in Washington, D.C., demonstrated the int...(BSGI) in clinical practice as an adjunct imaging ...at the annual meeting of the Radiological Society ... exhibit was to demonstrate how BSGI is used in th...
(Date:11/30/2009)...er in providing smart and efficient software to th...y®, evolutionizing work-from-home histopatholo...o; software used by 8 of the Top 10 Pharmaceutical...slide’ basis. , Mou...has announced another evolution in the histopathol...
(Date:11/30/2009)...mber 30 ApaTech, the rapidly growi...est growing,Biotech/Pharmaceutical/Medical Technol...ogy Fast 500 for EMEA (Europe, Middle East and Afr... companies, five-year revenue growth,for which Ap...od. This,achievement places ApaTech 9th overall in...
Breaking Biology Technology:The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 3Breast-Specific Gamma Imaging In Clinical Practice as an Adjunct Imaging Modality for Diagnosis of Breast Cancer 2Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS 2Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS 3ApaTech is Europe's Fastest Growing Lifescience Company 2ApaTech is Europe's Fastest Growing Lifescience Company 3ApaTech is Europe's Fastest Growing Lifescience Company 4
... the Force.com AppExchange saves time for reprint ...on process from within Salesforce CRM , ..., 2009 -- Reprints Desk, Inc., the content workflo...prints NRx for the Force.com AppExchange from sale...eprints NRx for the AppExchange is a procurement s...
...de Marketing Rights for Mometasone Furoate/Formote...H, N.J., May 19 Schering-Plough Corporation (NYSE...llaboration with Novartis for the development and ...ies for the treatment of asthma and chronic obstru...result in Schering-Plough assuming exclusive world...
...ulter, Inc. (NYSE: BEC ), a leading developer, m..., automate and innovate complex biomedical testing...offering of: , , , , $250 million of Se...t a rate of 6%, and , , , , , , $...d bear interest at a rate of 7%. , , , , ,...
Other Biology Technology:Reprints Desk Medical Reprint Service Now Available to Life Science Professionals on the Force.com AppExchange 2Reprints Desk Medical Reprint Service Now Available to Life Science Professionals on the Force.com AppExchange 3Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 2Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 3Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 4Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 5Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 6Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 7Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 8Beckman Coulter Prices $500 Million Senior Notes Offering 2Beckman Coulter Prices $500 Million Senior Notes Offering 3
(Date:11/30/2009)...searchers Ron Falta and Larry Murdoch have receive...t to study the safe storage of carbon dioxide in g...s surface. , With carbon dioxide emissions from ...use of global warming, geologic storage of the gas...ucing emissions using current technology. , "Geo...
(Date:11/30/2009)...sts and engineers from two of the nation,s largest...er Dec. 7 with leading academicians to explore the...ch like moving oil through a pipeline, the heart m...d clean, well-functioning pipes (or blood vessels)...ciently. Both industries also are crucial to our n...
(Date:11/30/2009)...rd registration rates and register online now for ...p://www.iofwco-ecceo10.org/ , WHAT: IOF WCO-EC...eoporosis Foundation (IOF) and the European Societ...s and Osteoarthritis (ESCEO). More than 5,000 part...end. The exciting scientific programme includes 12...
Breaking Biology News(10 mins):Similarities of pumping blood and oil examined 2Similarities of pumping blood and oil examined 3Atherotech Taps Canyons Medical Center Director Lipidologist as Chief Medical Officer 13254 1Atherotech Taps Canyons Medical Center Director Lipidologist as Chief Medical Officer 13254 2Atherotech Taps Canyons Medical Center Director Lipidologist as Chief Medical Officer 13254 3US HIFU Secures 245 Million Financing From MMV Financial 53103 1US HIFU Secures 245 Million Financing From MMV Financial 53103 2US HIFU Secures 245 Million Financing From MMV Financial 53103 3Ohio Man Top Bidder for Preakness Winners Halter First of Five Items in Horses Season Long Auction Series 53101 1Ohio Man Top Bidder for Preakness Winners Halter First of Five Items in Horses Season Long Auction Series 53101 2
...National Institutes of Health (NIH) has selected t...s, Environment and Health Initiative (GEI), a uniq...ntal scientists. , "This is ground-breaking res...ntribute to health and disease," said Department o.... "Researchers have long known that our genes, our...
...ive Optical Fingerprint Reader to be the Latest Ad...Hardware Suite, ATLANTA, Aug. 14 M2SYS Technolog... firm, announced today its partnership,with SecuGe...rprint reader,the Hamster Plus. The Hamster Plus ...hnology that automatically checks for the presence...
...tional Investors Convert Debentures to Equity, JE... Board: BMRX), a leading developer and supplier of... it is has provided notice to,certain holders of i...s,must surrender said warrants to the company by A...75,000 series B $0.10 warrants that it,has elected...
Other Biology News:Genes, Environment and Health Initiative invests in genetic studies, environmental monitoring 2Genes, Environment and Health Initiative invests in genetic studies, environmental monitoring 3Genes, Environment and Health Initiative invests in genetic studies, environmental monitoring 4Genes, Environment and Health Initiative invests in genetic studies, environmental monitoring 5Genes, Environment and Health Initiative invests in genetic studies, environmental monitoring 6Genes, Environment and Health Initiative invests in genetic studies, environmental monitoring 7Genes, Environment and Health Initiative invests in genetic studies, environmental monitoring 8Genes, Environment and Health Initiative invests in genetic studies, environmental monitoring 9M2SYS Partners with SecuGen Corporation to Support Market Leading Hamster Plus Fingerprint Reader with Auto-On Technology 2bioMETRX, Inc. Calls Series B Warrants 2
Sheep Anti-Human CATHEPSIN G Polyclonal Antibody, Unconjugated from AbD Serotec
DMRIE-C Reagent from Invitrogen
Rabbit Anti-TRANSFERRIN RECEPTOR Polyclonal Antibody, Unconjugated from AbD Serotec
Magnetic Separator (Re-usable) from BioVision
Biology Products: